XOMA Corporation (NASDAQ:XOMA) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.67 by 6 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys. 5 Brokerage Firms have advised hold.
XOMA Corporation (NASDAQ:XOMA): The mean estimate for the short term price target for XOMA Corporation (NASDAQ:XOMA) stands at $1.62 according to 3 Analysts. The higher price target estimate for the stock has been calculated at $3 while the lower price target estimate is at $1.
XOMA Corporation (NASDAQ:XOMA) witnessed a decline in the market cap on Tuesday as its shares dropped 2.01% or 0.0116 points. After the session commenced at $0.58, the stock reached the higher end at $0.58 while it hit a low of $0.541. With the volume soaring to 871,780 shares, the last trade was called at $0.565. The company has a 52-week high of $4.93. The company has a market cap of $68 million and there are 120,367,541 shares in outstanding. The 52-week low of the share price is $0.53.
XOMA Corporation has lost 7.38% in the last five trading days and dropped 16.91% in the last 4 weeks. XOMA Corporation has dropped 29.37% during the last 3-month period . Year-to-Date the stock performance stands at -57.52%.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).